TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Enhancing Strength Training in Nonagenarians
Brief Summary: The Health Enhancing Strength Training in Nonagenarians (STRONG) is a randomised control trial to assess the effectiveness of an aerobic and strength training program for improving functional capacity and quality of life in nonagenarians. Sixty (51 women) nonagenarians (age range: 90-102 years) who live in a geriatric nursing home will be randomly assigned to either a usual care (control) group (n=30) or an intervention (training) group (n=30). Participants allocated in the usual care group will receive general physical activity guidelines and participants allocated in the intervention group will also enroll in three weekly non-consecutive individualized training sessions (\~45-50 min each) during 8 weeks. The exercise program will consist of muscular strength \[with a special focus on leg press at 30% (start of the program) to 70% 1 repetition maximum (end)\] and aerobic exercises (cycle-ergometry during 3-5 to 15 minutes at 12-14 points in the rate of perceived exertion scale). Results from STRONG will help to better understand the potential of regular physical activity for improving the well-being of the oldest population groups.


Options:
A: Intervention Type: DEVICE; Name: BedEx Patient Occupancy Monitoring System; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: 8-week aerobic and strength training program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 8-week aerobic and strength training program; Assigned to Arm(s): 2
C: Arm Label: Person-centered Care; Type: EXPERIMENTAL; Interventions: Other: Person-centered Care, Other: Optimised Treatment | Arm Label: Optimised Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimised Treatment | Intervention Type: OTHER; Name: Person-centered Care; Assigned to Arm(s): Person-centered Care | Intervention Type: OTHER; Name: Optimised Treatment; Assigned to Arm(s): Optimised Treatment, Person-centered Care
D: Arm Label: Fall QI; Type: EXPERIMENTAL; Interventions: Behavioral: Falls QI | Arm Label: Connect & Falls QI; Type: EXPERIMENTAL; Interventions: Behavioral: Connect | Intervention Type: BEHAVIORAL; Name: Falls QI; Assigned to Arm(s): Fall QI | Intervention Type: BEHAVIORAL; Name: Connect; Assigned to Arm(s): Connect & Falls QI

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.


Options:
A: Arm Label: placebo + pioglitazone (with or without metformin); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: albiglutide + pioglitazone (with or without metformin); Type: EXPERIMENTAL; Interventions: Biological: albiglutide | Intervention Type: BIOLOGICAL; Name: albiglutide; Assigned to Arm(s): albiglutide + pioglitazone (with or without metformin) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo + pioglitazone (with or without metformin)
B: Arm Label: albiglutide weekly injection; Type: EXPERIMENTAL; Interventions: Biological: albiglutide | Arm Label: insulin glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine | Intervention Type: BIOLOGICAL; Name: albiglutide; Assigned to Arm(s): albiglutide weekly injection | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): insulin glargine
C: Arm Label: Vildagliptin + placebo to Gliclazide; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin, Drug: Placebo to Gliclazide | Arm Label: Gliclazide + placebo to Vildagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide, Drug: Metformin, Drug: Placebo to Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin, Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Gliclazide; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Vildagliptin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin, Drug: open-label metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glimepiride, Drug: open-label metformin | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: glimepiride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: open-label metformin; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Comparison of Pelvic Radiotherapy Alone vs Pelvic Radiotherapy Plus the LHRH Analogue Goserelin and Cyproterone Acetate in Carcinoma of the Prostate at High Risk for Metastasis
Brief Summary: RATIONALE: Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and cyproterone, may lessen the amount of androgens made by the body and reduces the amount of androgens available to the body. It is not yet know whether radiation therapy alone is more effective than radiation therapy given together with goserelin and cyproterone in treating patients with prostate cancer.

PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to giving radiation therapy together with goserelin and cyproterone in treating patients with prostate cancer that is at high risk for metastasis.


Options:
A: Intervention Type: DRUG; Name: antiandrogen therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: releasing hormone agonist therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: orchiectomy; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: cyproterone acetate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: goserelin acetate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bicalutamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder
Brief Summary: The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)


Options:
A: Arm Label: Olanzapine/Fluoxetine Combination; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine Fluoxetine Combination (OFC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olanzapine Fluoxetine Combination (OFC); Assigned to Arm(s): Olanzapine/Fluoxetine Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: DVS-SR 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: DVS-SR 100 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: Duloxetine 30 mg; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine 30 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder
Brief Summary: The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)


Options:
A: Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): Fluoxetine
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vilazodone 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: vilazodone 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 15 mg | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): vilazodone 30 mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: Duloxetine 30 mg; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine 30 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sapropterin as a Treatment for Autistic Disorder: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial
Brief Summary: This study is intended to provide a definitive test of the hypothesis that elevating sapropterin (tetrahydrobiopterin, a cofactor for several key brain enzymes)concentrations in the CNS will result in measurable improvements in core symptoms of autism in young individuals, under age 6 years. The study will entail a double-blind, placebo-controlled 16-week intervention.


Options:
A: Intervention Type: DRUG; Name: secretin, synthetic porcine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: secretin, biologically derived porcine; Assigned to Arm(s): N/A
B: Arm Label: sapropterin, 100 mg capsules; Type: EXPERIMENTAL; Interventions: Drug: sapropterin | Arm Label: Placebo, matching active drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: sapropterin; Assigned to Arm(s): sapropterin, 100 mg capsules | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, matching active drug
C: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alberta Population-based, Prospective Evaluation of the Quality of Life Outcomes and Economic Impacts of Bariatric Surgery
Brief Summary: The purpose is to determine the economic, clinical and quality of life outcomes of bariatric surgery and describe the consequences of protracted wait-times (\~ 2 years) for this procedure.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Preventive Health Record (IPHR) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "Standard" preventive care | Intervention Type: BEHAVIORAL; Name: Interactive Preventive Health Record (IPHR); Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: "Standard" preventive care; Assigned to Arm(s): Control
B: Arm Label: Electronic disease management decision support; Type: OTHER; Interventions: Other: Electronic disease management decision support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic disease management decision support; Assigned to Arm(s): Electronic disease management decision support
C: Arm Label: Bariatric Surgery Patient (Sx); Type: N/A; Interventions: N/A | Arm Label: Medical Treamtent (Mx); Type: N/A; Interventions: N/A | Arm Label: Wait-List (Wx); Type: N/A; Interventions: N/A
D: Arm Label: Portal training and home visits; Type: EXPERIMENTAL; Interventions: Behavioral: Portal training and home visits | Arm Label: portal training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Portal training | Intervention Type: BEHAVIORAL; Name: Portal training and home visits; Assigned to Arm(s): Portal training and home visits | Intervention Type: BEHAVIORAL; Name: Portal training; Assigned to Arm(s): portal training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hormonal Regulation of Body Weight Maintenance
Brief Summary: The investigators here propose to perform a collaborative clinical research effort including a randomized controlled trial investigating the mechanisms of weight maintenance and their relation to a lifestyle intervention in children, adolescents and adults. The detailed investigation and analysis of the variability and dynamics of the endocrine circuits responding to a negative energy balance and weight loss will be accompanied and enhanced by specific clinical projects targeting peripheral and central-nervous aspects of hormonal counter-regulation after weight loss. Mechanisms of endocrine counter-regulation and potential therapeutic approaches will be studied.


Options:
A: Arm Label: Lifestyle modification; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Kids-Houston program | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Healthy Kids-Houston program; Assigned to Arm(s): Lifestyle modification | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A
C: Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Arm Label: lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multimodal lifestyle intervention | Intervention Type: BEHAVIORAL; Name: multimodal lifestyle intervention; Assigned to Arm(s): lifestyle intervention | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hormonal Regulation of Body Weight Maintenance
Brief Summary: The investigators here propose to perform a collaborative clinical research effort including a randomized controlled trial investigating the mechanisms of weight maintenance and their relation to a lifestyle intervention in children, adolescents and adults. The detailed investigation and analysis of the variability and dynamics of the endocrine circuits responding to a negative energy balance and weight loss will be accompanied and enhanced by specific clinical projects targeting peripheral and central-nervous aspects of hormonal counter-regulation after weight loss. Mechanisms of endocrine counter-regulation and potential therapeutic approaches will be studied.


Options:
A: Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A
B: Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Arm Label: lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multimodal lifestyle intervention | Intervention Type: BEHAVIORAL; Name: multimodal lifestyle intervention; Assigned to Arm(s): lifestyle intervention | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety of Acidform Lubricant (Amphora) in Women at Low Risk for HIV-1 Infection
Brief Summary: Topical microbicides, substances that kill microbes, are being studied to prevent sexual transmission of HIV and other disease pathogens. In the future, topical microbicides may be applied vaginally to prevent both acquisition and transmission of HIV and other sexually transmitted infections (STIs). The purpose of this study is to compare the safety of daily applications of Acidform lubricant and HEC gel in healthy women at low risk for HIV infection and assess the effect of a microbicide candidate on the natural immunity women have to STI pathogens.


Options:
A: Arm Label: Dapivirine Vaginal Ring; Type: EXPERIMENTAL; Interventions: Combination Product: Dapivirine Vaginal Ring | Arm Label: Placebo Ring; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Placebo Ring | Intervention Type: COMBINATION_PRODUCT; Name: Dapivirine Vaginal Ring; Assigned to Arm(s): Dapivirine Vaginal Ring | Intervention Type: COMBINATION_PRODUCT; Name: Placebo Ring; Assigned to Arm(s): Placebo Ring
B: Intervention Type: DRUG; Name: Cellulose Sulfate Vaginal Gel (Microbicide); Assigned to Arm(s): N/A
C: Arm Label: Tenofovir 1% vaginal gel; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: Universal placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Universal placebo gel | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): Tenofovir 1% vaginal gel | Intervention Type: DRUG; Name: Universal placebo gel; Assigned to Arm(s): Universal placebo gel
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acidform Lubricant | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: HEC gel | Intervention Type: DRUG; Name: Acidform Lubricant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: HEC gel; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy
Brief Summary: To compare treatment outcome in patients with Crohn's disease with secondary loss of response to infliximab (i.e. initial good response follow by loss of response) treated according to current standards based only on clinical features versus treatment based on serum levels of infliximab and anti-infliximab antibody (Ab) status.


Options:
A: Arm Label: Top-down; Type: EXPERIMENTAL; Interventions: Drug: Infliximab, Drug: Azathioprine | Arm Label: Step-up; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone, Other: Exclusive enteral nutrition, Drug: Azathioprine | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Top-down | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Step-up | Intervention Type: OTHER; Name: Exclusive enteral nutrition; Assigned to Arm(s): Step-up | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Step-up, Top-down
B: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Biological: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Measurement of serum infliximab and anti-infliximab antibodies | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status | Intervention Type: PROCEDURE; Name: Measurement of serum infliximab and anti-infliximab antibodies; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: C